146 related articles for article (PubMed ID: 38238453)
1. The impact of social vulnerability index on survival following autologous stem cell transplant for multiple myeloma.
Salafian K; Mazimba C; Volodin L; Varadarajan I; Pilehvari A; You W; Knio ZO; Ballen K
Bone Marrow Transplant; 2024 Apr; 59(4):459-465. PubMed ID: 38238453
[TBL] [Abstract][Full Text] [Related]
2. Impact of autologous stem cell transplantation (ASCT) on progression free survival (PFS) in newly diagnosed multiple myeloma patients (NDMM) with high risk cytogenetic abnormalities.
Guman T; Sykora J
Bratisl Lek Listy; 2024; 125(1):9-11. PubMed ID: 38041839
[TBL] [Abstract][Full Text] [Related]
3. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.
Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D
Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040
[TBL] [Abstract][Full Text] [Related]
4. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
[TBL] [Abstract][Full Text] [Related]
5. [A Propensity Score Matching Study of Autologous Hematopoietic Stem Cell Transplantation and New Drug Chemotherapy for Newly Diagnosed Multiple Myeloma].
Yang FY; Wang HF; Xia LH; Wang QQ; Qian CJ; He J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):158-165. PubMed ID: 35123620
[TBL] [Abstract][Full Text] [Related]
6. Neutrophil to lymphocyte ratio (NLR) impact on the progression-free survival and overall survival of multiple myeloma patients treated with high-dose chemotherapy and autologous stem cell transplantation.
Mikulski D; Kościelny K; Nowicki M; Wawrzyniak E; Kalwas M; Kowalik M; Pryt M; Sęczkowska E; Świątek A; Wierzbowska A; Fendler W
Leuk Lymphoma; 2023 Jan; 64(1):98-106. PubMed ID: 36318865
[TBL] [Abstract][Full Text] [Related]
7. Circulating Plasma Cells at the Time of Collection of Autologous PBSC for Transplant in Multiple Myeloma Patients is a Negative Prognostic Factor Even in the Age of Post-Transplant Maintenance Therapy.
Cowan AJ; Stevenson PA; Libby EN; Becker PS; Coffey DG; Green DJ; Hyun TS; Fromm JR; Gopal AK; Holmberg LA
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1386-1391. PubMed ID: 29481870
[TBL] [Abstract][Full Text] [Related]
8. Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis.
Dhakal B; Szabo A; Chhabra S; Hamadani M; D'Souza A; Usmani SZ; Sieracki R; Gyawali B; Jackson JL; Asimakopoulos F; Hari PN
JAMA Oncol; 2018 Mar; 4(3):343-350. PubMed ID: 29302684
[TBL] [Abstract][Full Text] [Related]
9. Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma.
Lemieux C; Muffly LS; Rezvani A; Lowsky R; Iberri DJ; Craig JK; Frank MJ; Johnston LJ; Liedtke M; Negrin R; Weng WK; Meyer E; Shizuru J; Shiraz P; Arai S; Miklos DB; Sidana S
Bone Marrow Transplant; 2021 Feb; 56(2):368-375. PubMed ID: 32782351
[TBL] [Abstract][Full Text] [Related]
10. [The therapeutic effect and prognostic value of oligoclonal bands after autologous stem cell transplant in patients with multiple myeloma].
Shi QL; Xu Y; Wang J; Jin YY; Zhang R; Li JY; Chen LJ
Zhonghua Yi Xue Za Zhi; 2024 Feb; 104(7):514-520. PubMed ID: 38317363
[No Abstract] [Full Text] [Related]
11. Real-world advantage and challenge of post-autologous stem cell transplantation MRD negativity in high-risk patients with double-hit multiple myeloma.
Tao Y; Jin S; Yang D; Pan M; Ouyang W; Liu Y; Wang Y; Zhang W; Mi J
BMC Cancer; 2024 Apr; 24(1):406. PubMed ID: 38565996
[TBL] [Abstract][Full Text] [Related]
12. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients.
Terpos E; Apperley JF; Samson D; Giles C; Crawley C; Kanfer E; Olavarria E; Goldman JM; Rahemtulla A
Bone Marrow Transplant; 2003 Feb; 31(3):163-70. PubMed ID: 12621476
[TBL] [Abstract][Full Text] [Related]
13. Second stem cell transplantation for treatment of relapsed/refractory multiple myeloma after first autologous stem cell transplant: A 15-year retrospective institutional analysis.
Yadav N; Mirgh SP; Aggarwal M; Agrawal N; Mehta P; Khushoo V; Kapoor J; Bhatia N; Agrawal P; Ahmed R; Bhurani D
Indian J Cancer; 2023; 60(3):316-324. PubMed ID: 37787191
[TBL] [Abstract][Full Text] [Related]
14. Newly diagnosed multiple myeloma patients with CD56 expression benefit more from autologous stem cell transplantation.
Geng C; Zhou H; Wang H; Li Y; Leng Y; Zhang Z; Jian Y; Yang G; Chen W
BMC Cancer; 2022 Dec; 22(1):1349. PubMed ID: 36564753
[TBL] [Abstract][Full Text] [Related]
15. Impact of autologous stem cell transplantation on long term renal function and associated progression-free and overall survival in multiple myeloma.
Abudayyeh A; Lin H; Mamlouk O; Abdelrahim M; Saliba R; Rondon G; Martinez CS; Delgado R; Page V; Rajasekaran A; Sanders PW; Qazilbash M
Leuk Lymphoma; 2020 Dec; 61(13):3101-3111. PubMed ID: 32723196
[TBL] [Abstract][Full Text] [Related]
16. [Long-term follow-up of multiple myeloma after autologous hematopoietic stem cell transplantation: a single center results].
Sui WW; Zou DH; An G; Yi SH; Deng SH; Huang WY; Wang TY; Li J; Liu H; Fu MW; Lyu R; Liu W; Xu Y; Li ZJ; Zhao YZ; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2017 Jun; 38(6):499-504. PubMed ID: 28655093
[No Abstract] [Full Text] [Related]
17. Clinical factors associated with autologous stem cell transplantation outcomes in multiple myeloma: upfront transplant with MEL200 remains the standard of care.
Bostankolu Değirmenci B; Yegin ZA; Akdemir ÜÖ; Dede A; Gündem GG; Özkurt ZN; Atay LÖ; Yağcı M
Ann Hematol; 2024 Jan; 103(1):269-283. PubMed ID: 37880484
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Autologous Stem Cell Transplantation for Myeloma Patients with Suboptimal Response: A Multicenter Retrospective Analysis.
Suzuki K; Shimazu Y; Minakata D; Ikeda T; Takahashi H; Tsukada N; Kanda Y; Doki N; Nishiwaki K; Miwa A; Sawa M; Kataoka K; Hiramoto N; Ota S; Itagaki M; Ichinohe T; Atsuta Y; Yano S; Kawamura K;
Transplant Cell Ther; 2023 Nov; 29(11):688.e1-688.e13. PubMed ID: 37574125
[TBL] [Abstract][Full Text] [Related]
19. Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT).
Björkstrand B; Svensson H; Goldschmidt H; Ljungman P; Apperley J; Mandelli F; Marcus R; Boogaerts M; Alegre A; Remes K; Cornelissen JJ; Bladé J; Lenhoff S; Iriondo A; Carlson K; Volin L; Littlewood T; Goldstone AH; San Miguel J; Schattenberg A; Gahrton G
Bone Marrow Transplant; 2001 Mar; 27(5):511-5. PubMed ID: 11313685
[TBL] [Abstract][Full Text] [Related]
20. [Prognostic factors in newly diagnosed multiple myeloma patients with 1q21 amplification/gain treated with bortezomib-based regimens followed by autologous hematopoietic stem cell transplantation].
Huang WY; Zou DH; Liu W; An G; Xu Y; Sui WW; Deng SH; Li CW; Liu H; Li J; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2018 Jun; 39(6):496-500. PubMed ID: 30032568
[No Abstract] [Full Text] [Related]
[Next] [New Search]
